BioCryst Pharmaceuticals stock (US09058V1035): Nasdaq-listed biotech trades around USD 8 after recent short-interest data
Published on 06/04/2026 at 16:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioCryst Pharmaceuticals shares on the Nasdaq in the United States recently changed hands at about USD 8 per share, with the latest closing price at USD 8.25 on 06/03/2026, according to data compiled by MarketBeat based on Nasdaq trading figures as of that date.MarketBeat as of 06/03/2026
In parallel, short-interest statistics for BioCryst Pharmaceuticals show that, as of 05/15/2026, 36,106,472 shares were sold short, representing 14.97% of the public float and a days-to-cover ratio of 6.1 based on an average daily trading volume of 4.99 million shares, according to MarketBeat’s summary of the latest short-interest report.MarketBeat as of 05/15/2026
As of: 04/06/2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: BCRX
- Sector/industry: Biotechnology / pharmaceuticals
- Headquarters/country: Durham, United States
- Core markets: United States and selected international markets
- Key revenue drivers: Prescription drugs for rare diseases such as hereditary angioedema
- Home exchange/listing venue: Nasdaq (BCRX)
- Trading currency: USD
BioCryst Pharmaceuticals: core business model
BioCryst Pharmaceuticals focuses on researching, developing, and commercializing small-molecule therapies targeting rare and serious diseases, with revenue primarily generated from sales of its marketed treatments for hereditary angioedema and related indications.
Industry trends and competitive position
Specialty biotechnology companies that concentrate on rare-disease treatments operate in a segment where individual therapies can command premium pricing, but they must also compete against larger pharmaceutical groups that have substantial resources for clinical development and commercialization, especially in hereditary angioedema and other immunology-related indications.
Within this competitive landscape, BioCryst Pharmaceuticals positions itself as a focused player in oral and small-molecule therapies, which can offer an alternative to injectable treatments for some patients and thereby differentiate its product portfolio in niche but globally addressable markets.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on BioCryst Pharmaceuticals
The combination of a mid-teens short-interest level and an active biotech investor base often leads to lively discussions about potential catalysts and risks around the stock.
Conclusion
For BioCryst Pharmaceuticals, the latest available data point to an actively traded Nasdaq stock priced at a little over USD 8 per share in early June 2026, alongside a notable short-interest position representing nearly 15% of the float. These metrics, together with the company’s concentration on rare-disease therapies, frame the backdrop against which investors assess future clinical, regulatory, and commercial developments.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
